Blood pressure control by the nifedipine GITS-telmisartan combina

Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens. 2011;29:600–9.PubMedCrossRef 53. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee

to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996–3007.PubMedCrossRef AMN-107 nmr 54. Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician. 2000;61:3049–56.PubMed 55. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de FU, et al. Cardiovascular morbidity and C646 datasheet mortality in the Losartan Intervention P505-15 ic50 For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003. 56. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE,

Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–80.PubMedCrossRef 57. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.PubMedCrossRef 58. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

N Engl J Med. 2012;367:2204–13.PubMedCrossRef 59. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et Methane monooxygenase al. European Society of Hypertension position paper on abulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.PubMed 60. Head GA, Mihailidou AS, Duggan KA, Beilin LJ, Berry N, Brown MA, et al. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ. 2010;340:c1104.PubMedCentralPubMedCrossRef 61. Parati G, Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. Hypertens Res. 2014;37:187–93.PubMedCrossRef 62. Byrd JB, Brook RD. Arm position during ambulatory blood pressure monitoring: a review of the evidence and clinical guidelines. J Clin Hypertens (Greenwich). 2014;16:225–30.CrossRef 63. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26:1290–9.PubMedCrossRef 64.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>